Navigation Links
DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products, Therapeutic Biologics and Vaccines
Date:11/5/2009

Expert speakers from industry, Health Canada, EMEA, FDA, and PMDA will lead presentations at the 2nd DIA Conference on Harmonization of Risk Management Plans to be held December 10-11, 2009 in Washington, DC.

Horsham, PA (Vocus) November 5, 2009 -- Expert speakers from industry, Health Canada, EMEA, FDA, and PMDA will lead presentations at the 2nd DIA Conference on Harmonization of Risk Management Plans to be held December 10-11, 2009 in Washington, DC.

This conference will explore the essential components of RMP as they apply to medicinal products, therapeutic biologics, and vaccines with a focus on real and potential risks of products, which may be made available to patients and healthcare providers in different regions of the world. Sessions will include:

 
  • Risk Management Plans: What Do They Mean and What Are the Requirements for Each Region?
  • Risk Management Plans: What Have We Learned from RMPs About Managing Product Risks?
  • Developing an Harmonized Risk Management Plan
  • Successes and Opportunities for Harmonized Risk Management Plans
  • Risk Management Plans Town Meeting
  • Future Developments of RMPs and REMS
“The 2nd DIA Conference on Harmonization of Risk Management Plans will bring together global regulators and industry representatives to lead hands-on exercises and didactic presentations and to participate in panel discussions,” explains Program Chair William W. Gregory, Director, Safety and Risk Management, Pfizer Inc. “They will discuss why RMPs are important to your organization from a global regulatory perspective, the pros and cons of a global vs. local approach to developing RMPs, how an harmonized RMP can promote efficient, evidence-based decision-making to support the best use of marketed products, and how to develop an harmonized approach to creating an RMP.”

Register for the 2nd DIA Conference on Harmonization of Risk Management Plans.

About the Drug Information Association (DIA):
A non-profit, neutral, multidisciplinary, global, member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of drug development and medical product lifecycle management. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information, visit www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3163264.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products, Therapeutic Biologics and Vaccines
(Date:2/10/2016)... ... 2016 , ... Intermedix announced on Wednesday that it was ... medicine professional association, to support the organization's newly established physician group with a ... Medicine, or AAEM, seeks to empower emergency physicians to control their own practices. ...
(Date:2/10/2016)... Tarzana, CA (PRWEB) , ... February 10, 2016 ... ... Fernando Valley , announces that his office is now offering a variety of ... cheek enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other joint pain. ... often severe, with intense swelling and redness. It is triggered by the crystallization of ... adults are the most susceptible, according to the February 2016 issue of Harvard Men's ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 CSI Specialty Group (CSI) expanded its ... the Specialty Pharmacy Podcast. A free, weekly show, the ... real-world education, discussion and context amongst specialty pharmacy peers ... --> The Specialty Pharmacy Podcast, hosted by ... Group Suzette DiMascio, CHE, CMCE, CPC, is available for ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
(Date:2/10/2016)...  The ALS Association, in partnership with ALS Finding a ... a biomarker to track TDP43 aggregation. The successful team(s) with ... million investment. --> --> ... cells in the brain and the spinal cord. Eventually, people ... movement, which often leads to total paralysis and death within ...
Breaking Medicine Technology: